Current stock page

Stock Analysis

Insmed Incorporated (INSM) Stock Analysis

Insmed Incorporated (INSM) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

INSM Stock Analysis Summary

Insmed Incorporated (INSM) currently has an AIQ Score of 57/100, indicating a neutral setup. Momentum is the strongest factor at 61/100. Risk is the weakest current factor at 49/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

INSM at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$121.16
AIQ Score57/100
Overall ViewNeutral
Technical Analysis ConsensusStrong Buy
Market Cap$26.51B
P/E Ratio (TTM)-42.96
Forward P/E—
EPS (Q3 FY2026)-$0.46
Revenue (Q3 FY2026)$524.43M
Dividend Yield (TTM)0.00%
Beta0.55
Volume1.54M
52-week range$90.39-$212.75
RSI 1465.01
50-Day SMA$110.82
200-Day SMA$123.16
Analyst Price Target$191.13
Next EarningsFeb 18, 2027
As of Nov 13, 2026 · Market close

INSMInsmed Incorporated

Healthcare / Biotechnology

Low Priority

Above Peers

NeutralEdge 6/10
$121.16+$3.09 (+2.62%)

Latest quote

  • Momentum
    61
  • Value
    55
  • Quality
    58
  • Risk resilience
    49
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

INSM Stock Analysis Summary

Insmed Incorporated (INSM) currently has an AIQ Score of 57/100, indicating a neutral setup. Momentum is the strongest factor at 61/100. Risk resilience is the weakest current factor at 49/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Neutral

In a neutral regime, INSM has AIQ Score of 57/100 with Momentum base of 61/100 and fading Risk resilience at 49/100. Wait for component alignment before adding exposure.

Healthcare · 2.62% stock move · INSM classified in Biotechnology.

Current Evidence

NeutralINSM is in a neutral AIQ regime; Momentum is the strongest visible factor at 61/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is INSM Bullish or Bearish Right Now?

INSM currently has a neutral overall setup. Momentum is the strongest factor at 61/100, while Risk Resilience is weakest at 49/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.

Bull Case
  • - Price is +9.33% above its 50-day SMA.
  • - Analyst target implies +57.75% upside from the latest quote.
  • - Technical consensus has more buy votes than sell votes (36 vs 8).
Bear Case
  • - Risk Resilience is weak at 49/100.
  • - Price is -1.63% below its 200-day SMA.

Current Consensus

INSM's Technical Analysis Consensus is currently Strong Buy, with 36 buy, 2 neutral, and 8 sell votes. INSM's 14-day RSI is 65.01, which places the stock in a constructive momentum range. INSM's beta is 0.55, indicating lower market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in INSM?

The largest recent change in INSM is AIQ Score moving up by 1.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.

AIQ Score
+1.0
Momentum
+1.0
Quality
+1.0
Risk
+1.0

What Would Change the INSM Outlook?

The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

INSM Decision Framework

Public evidence layers, setup checks, and risk context for Insmed Incorporated.

Insmed Incorporated (INSM) Stock Analysis

Insmed Incorporated has an AIQ Score of 57/100 in a Neutral regime. Momentum is strongest at 61/100. Beta is 0.55, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextINSM is in a Neutral AIQ regime with score 57/100.
Signal ConflictThe primary conflict is that momentum leads at 61/100 while risk lags at 49/100.
Factor EvidenceMomentum 61/100 · Value 55/100 · Quality 58/100 · Risk 49/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthWait

Momentum is the strongest factor at 61/100.

TimingWait

Momentum is 61/100 and RSI (14) is 65.0.

Regime fitWait

INSM is in a Neutral regime at 57/100.

Risk controlFail

Risk factor is 49/100 with beta 0.55 and annual volatility 63.12%.

ConflictPass

Current conflict: momentum leads at 61/100 while risk lags at 49/100.

AIQ Score
57/100
Price
$121.16
Beta
0.55
RSI (14)
65

INSM Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

INSM Fundamentals

INSM valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$524.43M
Net income
-$100.32M
Free cash flow
-$42.09M
View full INSM fundamental analysis

INSM Technical Analysis

INSM technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Buy
RSI 14
65.01
Price vs SMA-50
+9.33%
View full INSM technical analysis

INSM Stock Catalysts

Track INSM earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 18, 2027
Analyst target
$191.13
News items
5
View INSM earnings and stock catalysts

INSM Dividend Analysis

INSM dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View INSM dividend history and analysis

INSM Financial Data

INSM revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$524.43M
EPS
-$0.46
Periods
8
View INSM financials

INSM Risk Analysis

INSM volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
0.55
Risk score
49/100
1Y volatility
63.12%
View INSM risk analysis

INSM Stock News

INSM stock news, market tone, recent headlines, and catalyst context.

News items
5
Updated
Nov 15, 2026
Sentiment
—
Read INSM stock news

INSM vs Biotechnology Peers

Current peer cohort: INSM · INVA · IRON · JAZZ · KOD. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
INSM
Current stock
57/10055/10061/10049/100-0.4863.12%Current
INVA
Innoviva, Inc.
67/10092/10043/10074/100-0.6425.21%INSM vs INVA
IRON
Disc Medicine, Inc.
65/100—75/10051/1000.163.55%INSM vs IRON
JAZZ
Jazz Pharmaceuticals plc
73/10079/10066/10073/1001.4738.64%INSM vs JAZZ
KOD
Kodiak Sciences Inc.
52/100—91/10044/1001.43205.61%INSM vs KOD
Pairwise Compare links: INVA · IRON · JAZZ · KODINSM vs INVAINSM vs IRONINSM vs JAZZINSM vs KODCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a INSM stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for INSM: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-42.96
As of Nov 13, 2026
Revenue growth
268.43%
Gross margin
84.26%
Current debt / equity
1.02
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$524.43M
Quarter net income
-$100.32M
Quarter free cash flow
-$42.09M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Mixed
Momentum
Bullish
RSI 14
65.01
MACD
3.69

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
49/100
Beta
0.55
Annual volatility
63.12%
Max drawdown
-56.54%

INSM Stock FAQ

What is INSM stock price today?

Insmed Incorporated's current stock price is $121.16. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is INSM bullish or bearish right now?

INSM's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is INSM's market cap?

INSM's market cap is $26.51B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is INSM's current P/E ratio?

INSM's current P/E ratio is -42.96 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is INSM's RSI?

INSM's 14-day RSI is 65.01 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is INSM above its 50-day and 200-day moving averages?

INSM is 9.33% from its 50-day SMA and -1.63% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is INSM's next earnings date?

INSM's next earnings date is currently listed as Feb 18, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does INSM pay a dividend?

INSM's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.